Cosentyx® (secukinumab) from Novartis is now approved to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is the only FDA-approved fully human biologic that directly inhibits interleukin-17A (IL-17A), a cytokine believed to be involved in the...
Kristine Kucera, PA-C, MPAS, DHS The World Health Organization declared October 10 Mental Health Day. With this, they acknowledged the hidden burdens of skin disease. A large survey focused on patients suffering from dermatological conditions showed that mental...
The FDA has approved the first and only fixed-dose, triple-combination topical treatment for acne. Cabtreo™ (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel 1.2%/0.15%/3.1% from Ortho Dermatologics is indicated for the topical treatment of acne...
In recognition of World Heart Day on September 29, the Dermatology Education Foundation (DEF) and the Society of Dermatology Physician Assistants (SDPA) speak with one voice to emphasize the significance of caregiver health and underscore the importance of healthcare...
Kristine Kucera, PA-C, MPAS, DHS A growing body of evidence has found that inflammatory skin diseases (ISDs) are associated with an increased risk for cardiovascular comorbidities. Patients with psoriasis have a documented increased for certain...
Kristine Kucera, PA-C, MPAS, DHS Hidradenitis suppurativa (HS) disproportionately affects women of childbearing age. As almost half of pregnancies in the United States are unplanned, dermatology practitioners must give special consideration to medication safety...
